In studies extending interests in HDACs beyond Treg cells, Dr. Matt Levine and his group have set up models of renal, hepatic, limb and lung IRI and begun, using genetic and pharmacologic approaches, to identify the effects of HDAC targeting on outcomes of ischemia/reperfusion injury (IRI) different tissues. This ongoing work is showing major differences in the roles of HDACs in different tissues, and provides a clinically relevant system in which to elucidate the biochemical functions of large HDAC-containing multiprotein nuclear complexes that regulate gene expression in vivo.